Abstract:Background Liver biopsy for the diagnosis of non-alcoholic steatohepatitis (NASH) is limited by its inherent invasiveness and sampling errors. Some studies have shown that cytokeratin-18 (CK-18) concentrations may be useful in predicting NASH, but results across studies have been inconsistent. The aim of this study was to identify the feasibility of CK-18 M30 concentrations as a non-invasive alternative to liver biopsy for diagnosing NASH. Methods Using an open online reporting form, individual data were collected from 15 registry centers on patients with biopsy-proven non-alcoholic fatty liver disease (NAFLD), and in all patients circulating CK-18 M30 levels were measured. These data included sex, age, ethnic, hypertension, diabetes, and serum alanine aminotransferase, but not personal health identifier. Individuals with NAFLD activity score (NAS) ≥ 5 including a score of ≥ 1 for each of steatosis, ballooning and lobular inflammation were diagnosed as having definite NASH; individuals with NAS ≤ 2 and no fibrosis were diagnosed as having non-alcoholic fatty liver (NAFL) (simple steatosis). (IDDF2022-ABS-0120 Table 1, IDDF2022-ABS-0120 Table 2). Results 2716 participants were screened and 1083 participants (172 with NAFL and 911 with NASH) were finally enrolled. Median CK-18 M30 levels were higher in patients with NASH than in those with NAFL (mean difference 150 U/L; standardized mean difference: 0.78 [0.62–0.95]), and there was interaction between CK-18 levels and serum alanine aminotransferase (P<0.001). CK-18 M30 levels were positively associated with histological NAS in most centers. The AUROC for NASH was 0.728 (95% CI: 0.691–0.764) and the Youden index was 275.7 U/L for CK-18 M30 (IDDF2022-ABS-0120 Figure 1. Diagnostic performances of CK-18 M30 level at the optimal cut-off value of 275.7 U/L. (A) Sensitivity in registry center. (B) Specificity in registry center. (C) Sensitivity in main characteristics subgroup. (D) Specificity in main characteristics subgroup). Sensitivity (54% [51–58%]) and positive predictive value (52%) were both not ideal. Conclusions This large multicenter registry study shows that CK-18 M30 measurement in isolation is of limited value for predicting NASH.

IDDF2022-ABS-0120 Hepatocyte Apoptosis Fragment Product Cytokeratin-18 M30 and Non-Alcoholic Steatohepatitis Risk Prediction: an International Registry Study

Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study

Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis

Clinical value of Serum CK-18 M30 levels in patients with nonalcoholic steatohepatitis

Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease.

Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease

Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4

Combined and Sequential Non-Invasive Approach to Diagnosing Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease and Persistently Normal Alanine Aminotransferase Levels.

Cytokeratin-18 as a Non-invasive Biomarker and its Association with Biochemical Parameters in the Diagnosis of Non-alcoholic Fatty Liver Disease

Prognostic Utility of Novel Biomarkers in Acute-on-chronic Liver Failure (ACLF) Associated with Hepatitis B: A Multicenter Prospective Study.

The Significance of IL-28B and CK-18 M30 Levels in the Diagnosis of Non-Alcoholic Steatohepatitis in SD Rats.

[Value of a Two-Step Approach with Cytokeratin-18 and Controlled Attenuation Parameter in Noninvasive Differential Diagnosis of Nonalcoholic Steatohepatitis].

Validation of Noninvasive Markers for HCC Risk Stratification in 1389 Patients With Biopsy-proven NAFLD

Technical Acoustic Measurements Combined with Clinical Parameters for the Differential Diagnosis of Nonalcoholic Steatohepatitis

Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease

A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease.

Disease-specific Mir-34A As Diagnostic Marker of Non-Alcoholic Steatohepatitis in a Chinese Population.

Serum Cytokeratin-18 levels as a prognostic biomarker in advanced liver disease: a comprehensive meta-analysis

The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis

A Novel Non-Invasive Approach Based on Serum Ceruloplasmin for Identifying Non-Alcoholic Steatohepatitis Patients in the Non-Diabetic Population